Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021

Business Wire October 12, 2021

REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile October 12, 2021

Revance Announces the Launch of OPUL(TM), the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices

Business Wire October 11, 2021

Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021

Business Wire September 16, 2021

Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting

Business Wire September 10, 2021

Revance to Participate in the Wells Fargo Securities Healthcare Conference

Business Wire September 2, 2021

Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery

Business Wire September 1, 2021

Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update

Business Wire August 5, 2021

Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Business Wire July 29, 2021

Revance to Participate in Upcoming Virtual Healthcare Conferences

Business Wire May 26, 2021

Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection

Business Wire May 26, 2021

Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update

Business Wire May 10, 2021

Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021

Business Wire May 3, 2021

Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA's 24-Week Long Duration Profile Across Multiple Female Age Cohorts

Business Wire April 27, 2021

Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

Business Wire April 27, 2021

Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021

Business Wire April 23, 2021

Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference

Business Wire April 6, 2021

Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting

Business Wire April 1, 2021

Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021

Business Wire March 22, 2021

Revance to Participate in Upcoming Virtual Healthcare Conferences

Business Wire February 24, 2021